BioCardia CEO Issued Shareholder Letter To Provide Update; Milestone Includes Submission For Japan's Pharmaceutical and Medical Device Agency Approval Planned For End Of 2026; Driving To Enroll Confirmatory CardiAMP HF II Trial In US

BioCardia Says FDA Finalized Pre-Submission Meeting Minutes For Helix Transendocardial Delivery Catheter; Plans Follow-On Pre-Submission This Quarter Toward Potential De Novo Approval

8-K filing — BioCardia, Inc. (BCDA)

Filed: 2026-08-24 AccNo: 0001437749-26-028778 Size: 178 KB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

BioCardia Q2 EPS $(0.13) Beats $(0.18) Estimate

BioCardia (NASDAQ:BCDA) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.18) by 27.78 percent. This is a 67.5 percent increase over losses of $(0.40) per share from the